BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10822537)

  • 1. Enantioselective synthesis of saframycin A and evaluation of antitumor activity relative to ecteinascidin/saframycin hybrids.
    Martinez EJ; Corey EJ
    Org Lett; 1999 Jul; 1(1):75-7. PubMed ID: 10822537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic studies on ecteinascidin-743: constructing a versatile pentacyclic intermediate for the synthesis of ecteinascidins and saframycins.
    Jin W; Metobo S; Williams RM
    Org Lett; 2003 Jun; 5(12):2095-8. PubMed ID: 12790537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and cytotoxic evaluation of some cribrostatin-ecteinascidin analogues.
    Wright BJ; Chan C; Danishefsky SJ
    J Nat Prod; 2008 Mar; 71(3):409-14. PubMed ID: 18278868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B.
    Cuevas C; Pérez M; Martín MJ; Chicharro JL; Fernández-Rivas C; Flores M; Francesch A; Gallego P; Zarzuelo M; de La Calle F; García J; Polanco C; Rodríguez I; Manzanares I
    Org Lett; 2000 Aug; 2(16):2545-8. PubMed ID: 10956543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.
    Zewail-Foote M; Hurley LH
    J Med Chem; 1999 Jul; 42(14):2493-7. PubMed ID: 10411470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions?
    García-Nieto R; Manzanares I; Cuevas C; Gago F
    J Med Chem; 2000 Nov; 43(23):4367-9. PubMed ID: 11087561
    [No Abstract]   [Full Text] [Related]  

  • 7. Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
    Dong W; Liu W; Yan Z; Liao X; Guan B; Wang N; Liu Z
    Eur J Med Chem; 2012 Mar; 49():239-44. PubMed ID: 22284268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total synthesis of ecteinascidin 743.
    Endo A; Yanagisawa A; Abe M; Tohma S; Kan T; Fukuyama T
    J Am Chem Soc; 2002 Jun; 124(23):6552-4. PubMed ID: 12047173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
    Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
    [No Abstract]   [Full Text] [Related]  

  • 10. The potent anticancer compound ecteinascidin-743 (ET-743) as its 2-propanol disolvate.
    Sainz-Diaz CI; Manzanares I; Francesch A; Garcia-Ruiz J
    Acta Crystallogr C; 2003 Apr; 59(Pt 4):O197-8. PubMed ID: 12682407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
    Aune GJ; Furuta T; Pommier Y
    Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
    Martinez EJ; Owa T; Schreiber SL; Corey EJ
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3496-501. PubMed ID: 10097064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA.
    Marco E; David-Cordonnier MH; Bailly C; Cuevas C; Gago F
    J Med Chem; 2006 Nov; 49(23):6925-9. PubMed ID: 17154523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents.
    Martinez EJ; Corey EJ
    Org Lett; 2000 Apr; 2(7):993-6. PubMed ID: 10768205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ecteinascidin-743.
    Held-Warmkessel J
    Clin J Oncol Nurs; 2003; 7(3):313-9. PubMed ID: 12793338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
    Takebayashi Y; Pourquier P; Yoshida A; Kohlhagen G; Pommier Y
    Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7196-201. PubMed ID: 10377391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of saframycins. X. Transformation of (-)-saframycin A to (-)-saframycin Mx type compound with the structure proposed for saframycin E.
    Saito N; Harada S; Nishida M; Inouye I; Kubo A
    Chem Pharm Bull (Tokyo); 1995 May; 43(5):777-82. PubMed ID: 7553964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practical synthesis of the ABC ring model of ecteinascidins.
    Saito N; Tachi M; Seki R; Kamayachi H; Kubo A
    Chem Pharm Bull (Tokyo); 2000 Oct; 48(10):1549-57. PubMed ID: 11045468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric total synthesis of (-)-saframycin A from L-tyrosine.
    Dong W; Liu W; Liao X; Guan B; Chen S; Liu Z
    J Org Chem; 2011 Jul; 76(13):5363-8. PubMed ID: 21612294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.
    Hurley LH; Zewail-Foote M
    Adv Exp Med Biol; 2001; 500():289-99. PubMed ID: 11764956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.